Producer and Host
Abigail is a recovering lawyer living in Orlando, Florida with her husband, two boys and a very spoiled cat. She has been living with Stage IV Metastatic Breast Cancer since 2017 and has found a tremendous sense of purpose through advocacy. Abigail serves as the Director of Mentorship for Project Life, as the Chair of the MBC Leadership Committee for Surviving Breast Cancer, as a research advocate with FORCE, as a RISE Legacy advocate for Young Survival Coalition, moderates an MBC support group with the 305 Pink Pack and a volunteer with a variety of organizations focused on serving the breast cancer and the MBC community. You can find her musings online at No Half Measures and on quite a few social media platforms.
PI(3)King the right target after CDK4/6 inhibitors fail patients is an exciting area of research and FDA approval. Now that there are multiple options approved by the FDA and more to come, patients have more treatment choices. Join host Abigail Johnston as she interviews 2 patients who give us their perspective on these advances, as well as a doctor whose scientific research has led the way identifying PIK3CA mutations as a cancer genomic biomarker.